National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

recombinant modified vaccinia Ankara-5T4 vaccine
A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:recombinant MVA-5T4 vaccine
recombinant pox virus encoding 5T4 vaccine
vaccinia-5T4 antigen vaccine
US brand name:TroVax
Foreign brand name:TroVax
Abbreviation:rV-5T4 VAC



Previous:recombinant interleukin-6, recombinant interleukin-7, recombinant macrophage colony-stimulating factor, recombinant MAGE-3.1 antigen, recombinant MAGE-A3 antigen-specific cancer immunotherapeutic GSK1203486A
Next:recombinant nematode anticoagulant protein c2, recombinant parathyroid hormone, recombinant platelet factor 4, recombinant soluble human CD4 protein, recombinant thyroid-stimulating hormone

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov